ERBB2 and breast cancer: In a HER2(+) breast cancer model, HER2-CAR T cells upregulated PD-1 after incubation with target cells, and the PD-1 blockade did increase CAR T cell proliferation, IFN-γ production, and granzyme B expression in vitro while enhancing in vivo cytotoxicity [143].